How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Sotatercept (biological)
How long the study runs: Study runs about 91 months (dates as stated)
About the drug or intervention: Sotatercept — biological: Sotatercept SC injection every 3 weeks
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 815
Started: 2021-05-12
Last checked: 2026-10

Plain English Summary

What is this study?

• Testing a new treatment for pulmonary arterial hypertension
• Phase3 - 815 participants
• Researchers are looking for more ways to treat PAH

Who can take part?

• Ages 18 Years and over
• Diagnosed with pulmonary arterial hypertension

Where?

• Cambridge - Papworth Hospital NHS Foundation Trust ( Site 1208)
• Glasgow - Golden Jubilee National Hospital ( Site 1204)
• London - Royal Free Hospital ( Site 1202)
• London - Royal Brompton Hospital ( Site 1206)
• +3 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can treat symptoms of PAH but do not stop PAH from getting worse. Sotatercept is a study medicine designed to treat PAH. It is a targeted therapy, which is a treatment that works on certain proteins that play a role in causing PAH. This is a long-term follow-up (LTFU) study. People who took part in certain other studies testing sotatercept for PAH may be able to join this study. The goal of this study is to learn about the long-term safety of sotatercept and if people tolerate it when taken with standard PAH treatment over a longer period of time.

More detail

LTFU PAH sotatercept study MK-7962-004 (Obsolete Identifier: NCT04796337) has been incorporated into the current MK-7962-038 (NCT07218029) study for administrative reasons. The MK-7962-004 study is no longer enrolling participants and will be formally closed. Only those who participated in MK-7962-004 may be eligible to continue into MK-7962-038.

Pulmonary Arterial Hypertension

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

Treatment history

Treatments you must have had:

✓ the ability to understand and provide documented informed consent

What the study is looking for

✓The main inclusion criteria include but are not limited to the following:
✓Has completed their current respective PAH sotatercept clinical study and its requirements, and must not have...
✓Is willing to adhere to the study visit schedule, and understands and will comply with all protocol requirements
✓Must have the ability to understand and provide documented agreement to take part

Who cannot take part

✗The main exclusion criteria include but are not limited to the following:
✗Did not participate in a sotatercept PAH parent study
✗Missed more than the equivalent of 4 consecutive doses between the end of parent study and the start of this study.
✗Presence of an ongoing serious adverse event that occurred during a PAH sotatercept clinical study that is assessed...
✗Is a female who is pregnant or breastfeeding

See the full criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has completed their current respective PAH sotatercept clinical study and its requirements, and must not have discontinued early * Is willing to adhere to the study visit schedule, and understands and will comply with all protocol requirements * Must have the ability to understand and provide documented informed consent Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Did not participate in a sotatercept PAH parent study * Missed more than the equivalent of 4 consecutive doses between the end of parent study and the start of this study. * Presence of an ongoing serious adverse event that occurred during a PAH sotatercept clinical study that is assessed to be possibly or probably related to sotatercept * Is a female who is pregnant or breastfeeding * Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study * Is currently enrolled in another investigational product study other than a sotatercept study * Is incapacitated

Where Is This Study? (7 UK sites)

Papworth Hospital NHS Foundation Trust ( Site 1208)

Cambridge CB2 0AY, United Kingdom

Golden Jubilee National Hospital ( Site 1204)

Glasgow G81 4DY, United Kingdom

Royal Free Hospital ( Site 1202)

London NW3 2QG, United Kingdom

Hospital R&D contact (matched)

Natasha Ajraam

rf-tr.randd@nhs.net 020 375 82150

Royal Brompton Hospital ( Site 1206)

London SW3 6NP, United Kingdom

Hammersmith Hospital ( Site 1203)

London W12 0HS, United Kingdom

Freeman Hospital ( Site 1205)

Newcastle upon Tyne NE7 7DN, United Kingdom

Royal Hallamshire Hospital ( Site 1207)

Sheffield S10 2JF, United Kingdom

Data sourced from ClinicalTrials.gov · Last verified: 2026-10